e-ISSN 1309-2545      ISSN 1301-062X
TR    ENG
 

Download Current Issue.

Volume : 25 Issue : 3 Year : 2019

Current Issue Archive Popular Articles Ahead of Print Submit Your Article Login
Turkish Journal of Neurology Indexed By
 
  Search






Use of Mitoxantrone in Early Secondary Progressive Multiple Sclerosis: An Observational Study of 48 Patients with Clinical and MRI Outcomes [Turk J Neurol]
Turk J Neurol. 2009; 15(2): 64-70

Use of Mitoxantrone in Early Secondary Progressive Multiple Sclerosis: An Observational Study of 48 Patients with Clinical and MRI Outcomes

Ahmet Kasım Kılıç1, Aslı Kurne1, Birgül Baştan1, İrem Çıkrıkçı1, Demet Funda Baş1, Mine Buluş3, Neslihan Eker3, Gülşen Kışlak3, Elif Bulut2, Kader Karlı Oğuz2, Rana Karabudak1
1Faculty Of Medicine, University Of Hacettepe, Department Of Neurology, Ankara, Turkey
2Faculty Of Medicine, University Of Hacettepe, Department Of Radiology, Ankara, Turkey
3Faculty Of Medicine, University Of Hacettepe, Department Of Pharmacy, Subdivision Of Chemotherapy, Ankara, Turkey

OBJECTIVE: To report the clinical follow-up, side effects, and magnetic resonance imaging (MRI) findings of mitoxantrone treatment
in patients in the early phase of secondary progressive and exacerbating relapsing-remitting multiple sclerosis.
METHODS: Patients that completed and/or were undergoing treatment between 2001 and 2008 were included in the
study. All patients were definitive progressive multiple sclerosis patients and met ‘non-responder’ criteria for immunomodulatory the-
rapy. They did not have active infection, cardiac disease, or any contraindication for immunosuppressive treatment. Baseline comp-
lete blood count, liver function tests, and transthoracic echocardiography were performed. Mitoxantrone was given as induction the-
rapy (1 dose per month for 3 months) and then as maintenance therapy (with 3 month periods, 12 mg/m2 until to the cumulative
dose was reached). Patients were followed-up regularly for the appearance of any side effects.
RESULTS: The study included 33 female and 15 male patients. Mean age was 36.6 ± 7.8 years, mean disease duration was 9.38 ±
4.8 years, mean expanded disease severity scale (EDSS) score was 5.8, and mean treatment duration was 11.16 ± 7.4 months. Fol-
lowing the end of treatment, 17 patients were stabilized, 10 improved, and 14 progressed. There were no side effects observed du-
ring or after treatment in 16 patients. Among the other 32 patients, the observed side effects were as follows: nausea (n= 18), per-
manent leucopenia (n= 1), transient thrombocytopenia (n= 4), alopecia (n= 13), neutropenic fever (n= 1), and amenorrhea (n= 18).
MRI follow-up was performed in a subgroup of patients and showed that the lesion loads were stabilized.
CONCLUSION: We reported the efficacy, and clinical and MRI follow-up results of multiple sclerosis patients treated with mitoxantro-
ne. Patient selection and therapy timing was very important for maximum efficacy. Patients that responded to mitoxantrone treat-
ment benefited beginning with the induction phase and their disability was limited or improved.

Keywords: Multiple sclerosis, immunosuppressive agents, mitoxantrone


Ahmet Kasım Kılıç, Aslı Kurne, Birgül Baştan, İrem Çıkrıkçı, Demet Funda Baş, Mine Buluş, Neslihan Eker, Gülşen Kışlak, Elif Bulut, Kader Karlı Oğuz, Rana Karabudak. Use of Mitoxantrone in Early Secondary Progressive Multiple Sclerosis: An Observational Study of 48 Patients with Clinical and MRI Outcomes. Turk J Neurol. 2009; 15(2): 64-70

Corresponding Author: Ahmet Kasım Kılıç, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar




 
© Copyright 2019 Turkish Journal of Neurology
Home        |        Contact
LookUs & OnlineMakale